CTMX

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing antibody therapeutics using its proprietary Probody therapeutic technology platform. The company's approach involves creating conditionally activated antibodies that remain inactive in healthy tissue but become active in the tumor microenvironment, potentially reducing systemic toxicity while maintaining anti-cancer efficacy. CytomX is developing a pipeline of cancer treatments targeting multiple solid tumor types, with programs in immuno-oncology and targeted therapy. The company has partnerships with major pharmaceutical companies to advance its technology platform.